Inclusion of minorities and women in cancer clinical trials, a decade later: Have we improved?

Kat Kwiatkowski, Kathryn Coe, John C. Bailar, G. Marie Swanson

    Research output: Contribution to journalArticle

    50 Citations (Scopus)

    Abstract

    BACKGROUND Inclusion of diverse groups of participants in cancer clinical trials is an important methodological and clinical issue. The quality of the science and generalizability of results depends on the inclusion of study participants who represent all populations among whom these treatment and prevention approaches will be used. METHODS We conducted a systematic review using OVID as the primary source of reports included. Based on 304 peer-reviewed publications, diversity in the inclusion and reporting of study participants during a decade of cancer treatment and prevention trials (2001-2010) is summarized. Recommendations are made for improvements in the science and reporting of cancer clinical trials. RESULTS Of the 277 treatment trials and 27 prevention trials included in this report, more than 80% of participants were white and 59.8% were male. In the recent decade, race and sex are rarely used as selection criteria unless the trial is focused on a sex-specific cancer. CONCLUSIONS Women and racial/ethnic minorities remain severely underrepresented in cancer clinical trials, thus limiting the generalizability of cancer clinical research.

    Original languageEnglish
    Pages (from-to)2956-2963
    Number of pages8
    JournalCancer
    Volume119
    Issue number16
    DOIs
    StatePublished - 2013

    Fingerprint

    Clinical Trials
    Neoplasms
    Patient Selection
    Publications
    Therapeutics
    Research
    Population

    Keywords

    • cancer clinical trials
    • health disparities
    • participant selection
    • prevention
    • treatment

    ASJC Scopus subject areas

    • Cancer Research
    • Oncology

    Cite this

    Inclusion of minorities and women in cancer clinical trials, a decade later : Have we improved? / Kwiatkowski, Kat; Coe, Kathryn; Bailar, John C.; Swanson, G. Marie.

    In: Cancer, Vol. 119, No. 16, 2013, p. 2956-2963.

    Research output: Contribution to journalArticle

    Kwiatkowski, K, Coe, K, Bailar, JC & Swanson, GM 2013, 'Inclusion of minorities and women in cancer clinical trials, a decade later: Have we improved?', Cancer, vol. 119, no. 16, pp. 2956-2963. https://doi.org/10.1002/cncr.28168
    Kwiatkowski, Kat ; Coe, Kathryn ; Bailar, John C. ; Swanson, G. Marie. / Inclusion of minorities and women in cancer clinical trials, a decade later : Have we improved?. In: Cancer. 2013 ; Vol. 119, No. 16. pp. 2956-2963.
    @article{3eac0a17bb4648ee9f892d3be87cfef8,
    title = "Inclusion of minorities and women in cancer clinical trials, a decade later: Have we improved?",
    abstract = "BACKGROUND Inclusion of diverse groups of participants in cancer clinical trials is an important methodological and clinical issue. The quality of the science and generalizability of results depends on the inclusion of study participants who represent all populations among whom these treatment and prevention approaches will be used. METHODS We conducted a systematic review using OVID as the primary source of reports included. Based on 304 peer-reviewed publications, diversity in the inclusion and reporting of study participants during a decade of cancer treatment and prevention trials (2001-2010) is summarized. Recommendations are made for improvements in the science and reporting of cancer clinical trials. RESULTS Of the 277 treatment trials and 27 prevention trials included in this report, more than 80{\%} of participants were white and 59.8{\%} were male. In the recent decade, race and sex are rarely used as selection criteria unless the trial is focused on a sex-specific cancer. CONCLUSIONS Women and racial/ethnic minorities remain severely underrepresented in cancer clinical trials, thus limiting the generalizability of cancer clinical research.",
    keywords = "cancer clinical trials, health disparities, participant selection, prevention, treatment",
    author = "Kat Kwiatkowski and Kathryn Coe and Bailar, {John C.} and Swanson, {G. Marie}",
    year = "2013",
    doi = "10.1002/cncr.28168",
    language = "English",
    volume = "119",
    pages = "2956--2963",
    journal = "Cancer",
    issn = "0008-543X",
    publisher = "John Wiley and Sons Inc.",
    number = "16",

    }

    TY - JOUR

    T1 - Inclusion of minorities and women in cancer clinical trials, a decade later

    T2 - Have we improved?

    AU - Kwiatkowski, Kat

    AU - Coe, Kathryn

    AU - Bailar, John C.

    AU - Swanson, G. Marie

    PY - 2013

    Y1 - 2013

    N2 - BACKGROUND Inclusion of diverse groups of participants in cancer clinical trials is an important methodological and clinical issue. The quality of the science and generalizability of results depends on the inclusion of study participants who represent all populations among whom these treatment and prevention approaches will be used. METHODS We conducted a systematic review using OVID as the primary source of reports included. Based on 304 peer-reviewed publications, diversity in the inclusion and reporting of study participants during a decade of cancer treatment and prevention trials (2001-2010) is summarized. Recommendations are made for improvements in the science and reporting of cancer clinical trials. RESULTS Of the 277 treatment trials and 27 prevention trials included in this report, more than 80% of participants were white and 59.8% were male. In the recent decade, race and sex are rarely used as selection criteria unless the trial is focused on a sex-specific cancer. CONCLUSIONS Women and racial/ethnic minorities remain severely underrepresented in cancer clinical trials, thus limiting the generalizability of cancer clinical research.

    AB - BACKGROUND Inclusion of diverse groups of participants in cancer clinical trials is an important methodological and clinical issue. The quality of the science and generalizability of results depends on the inclusion of study participants who represent all populations among whom these treatment and prevention approaches will be used. METHODS We conducted a systematic review using OVID as the primary source of reports included. Based on 304 peer-reviewed publications, diversity in the inclusion and reporting of study participants during a decade of cancer treatment and prevention trials (2001-2010) is summarized. Recommendations are made for improvements in the science and reporting of cancer clinical trials. RESULTS Of the 277 treatment trials and 27 prevention trials included in this report, more than 80% of participants were white and 59.8% were male. In the recent decade, race and sex are rarely used as selection criteria unless the trial is focused on a sex-specific cancer. CONCLUSIONS Women and racial/ethnic minorities remain severely underrepresented in cancer clinical trials, thus limiting the generalizability of cancer clinical research.

    KW - cancer clinical trials

    KW - health disparities

    KW - participant selection

    KW - prevention

    KW - treatment

    UR - http://www.scopus.com/inward/record.url?scp=84881480382&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84881480382&partnerID=8YFLogxK

    U2 - 10.1002/cncr.28168

    DO - 10.1002/cncr.28168

    M3 - Article

    C2 - 23674318

    AN - SCOPUS:84881480382

    VL - 119

    SP - 2956

    EP - 2963

    JO - Cancer

    JF - Cancer

    SN - 0008-543X

    IS - 16

    ER -